Editas Medicine stands out as a leader in the field of genomic medicine, leveraging the potential of CRISPR gene editing technology to develop treatments for serious diseases. The company fosters a vibrant culture, encouraging collaboration and resilience among its team of 'Editors', and is committed to manufacturing and commercializing durable, precision genomic medicines. With a robust pipeline of treatments in development, Editas Medicine is not only repairing broken genes but also shaping the future of medicine.